Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Chersich

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Globalization and Health|September 8, 2016
Mapping of research on maternal health interventions in low- and middle-income countries: a review of 2292 publications between 2000 and 2012Matthew Chersich, Duane Blaauw, Mari Dumbaugh, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trialWillem D F Venter, Simiso Sokhela, Bryony Simmons, et al.
Open Forum Infectious Diseases|March 26, 2024
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral RegimensSimiso Sokhela, Willem D F Venter, Bronwyn Bosch, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Globalization and Health|September 8, 2016
Mapping of research on maternal health interventions in low- and middle-income countries: a review of 2292 publications between 2000 and 2012Matthew Chersich, Duane Blaauw, Mari Dumbaugh, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trialWillem D F Venter, Simiso Sokhela, Bryony Simmons, et al.
Open Forum Infectious Diseases|March 26, 2024
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral RegimensSimiso Sokhela, Willem D F Venter, Bronwyn Bosch, et al.
Pageof 9